Cagrilintide(1415456-99-3)Weight loss Peptides

Cagrilintide is an investigational, long-acting dual amylin and calcitonin receptor agonist (DACRA) designed primarily for chronic weight management and the treatment of type 2 diabetes. By mimicking the actions of the natural pancreatic hormone amylin, it targets the brain’s appetite regulation centers to significantly enhance satiety and reduce food cravings. Additionally, cagrilintide slows gastric emptying and suppresses post-meal glucagon secretion, which helps stabilize blood glucose levels. Typically administered as a weekly subcutaneous injection, it is frequently studied and utilized in combination with GLP-1 receptor agonists (such as semaglutide in the combination known as CagriSema) to achieve synergistic, highly effective weight loss.